Gland Pharma Limited (GLAND) - Total Liabilities
Based on the latest financial reports, Gland Pharma Limited (GLAND) has total liabilities worth Rs22.37 Billion INR (≈ $241.96 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore GLAND cash flow conversion to assess how effectively this company generates cash.
Gland Pharma Limited - Total Liabilities Trend (2017–2025)
This chart illustrates how Gland Pharma Limited's total liabilities have evolved over time, based on quarterly financial data. Check GLAND asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Gland Pharma Limited Competitors by Total Liabilities
The table below lists competitors of Gland Pharma Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Empresas CMPC
SN:CMPC
|
Chile | CL$10.48 Billion |
|
Beijing Vantone Real Estate Co Ltd
SHG:600246
|
China | CN¥2.61 Billion |
|
TVS Holdings Limited
NSE:TVSHLTD
|
India | Rs473.56 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥17.59 Billion |
|
Rev Group Inc
NYSE:REVG
|
USA | $783.70 Million |
|
Erasca Inc
NASDAQ:ERAS
|
USA | $70.98 Million |
|
CRRC Corporation Limited
F:C2L
|
Germany | €334.70 Billion |
|
Marathon Digital Holdings Inc
NASDAQ:MARA
|
USA | $3.98 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Gland Pharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Gland Pharma Limited (GLAND) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gland Pharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gland Pharma Limited (2017–2025)
The table below shows the annual total liabilities of Gland Pharma Limited from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs20.74 Billion ≈ $224.31 Million |
+7.06% |
| 2024-03-31 | Rs19.37 Billion ≈ $209.52 Million |
+136.61% |
| 2023-03-31 | Rs8.19 Billion ≈ $88.55 Million |
+21.13% |
| 2022-03-31 | Rs6.76 Billion ≈ $73.11 Million |
+14.03% |
| 2021-03-31 | Rs5.93 Billion ≈ $64.11 Million |
+34.80% |
| 2020-03-31 | Rs4.40 Billion ≈ $47.56 Million |
-33.52% |
| 2019-03-31 | Rs6.62 Billion ≈ $71.54 Million |
+27.44% |
| 2018-03-31 | Rs5.19 Billion ≈ $56.14 Million |
+35.21% |
| 2017-03-31 | Rs3.84 Billion ≈ $41.52 Million |
-- |
About Gland Pharma Limited
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic … Read more